Aktis肿瘤学在美国IPO筹集了3.18亿美元,按每股18美元的价格定价,并将Nasdaq列为AKTS。 Aktis Oncology raised $318 million in a U.S. IPO, pricing at $18 per share and listing on Nasdaq as AKTS.

Aktis肿瘤公司将其规模扩大的美国IPO的价格定为每股18美元,筹集了约3.18亿美元,并争取价值高达9.454亿美元。 Aktis Oncology priced its upsized U.S. IPO at $18 per share, raising about $318 million and aiming for a valuation of up to $945.4 million. 该公司以美国为基地,重点开发固态肿瘤的治疗方法,开始以“AKTS”为标志进行Nasdaq的交易。 The company, based in the U.S. and focused on developing treatments for solid tumors, began trading on Nasdaq under the symbol "AKTS." 与原计划相比,这项提议的规模有所扩大,反映了投资者对生物技术公司推动新型癌症治疗的兴趣浓厚。 The offering, which increased in size from its original plan, reflects strong investor interest in biotech firms advancing novel cancer therapies.